The Toronto oncological MRI agent spinout has been backed by Facit’s Prospects Oncology vehicle, to target applications including the identification and treatment of tumours in the brain.

Newly-founded MIT food pathogen sensor spinout Xibus has secured seed funding to develop its technology, which utilises synthetic particles to identify bacterial contamination.

Big Idea Ventures will invest in alternative protein and plant-based food developers, and has secured about a third of its $100m Tyson Foods-backed fund.

Novo and Sanofi Ventures returned to reinvest in Yale spinout Inozyme Pharma as it looks to advance its lead mineralisation disorder drug towards the clinic.

The aviation company is set to buy the JetEdge-backed private-flight booking platform, which was valued at more than $1.6bn in 2016, in an all-share transaction.

Novo and Sanofi Ventures returned to reinvest in Inozyme Pharma as it looks to advance its lead mineralisation disorder drug towards the clinic.

Varian Medical Systems co-led the series B round, which will fund the development of ABK Biomedical's embolic therapies.

HPE, Cisco Investments, Ericsson and Robert Bosch all contributed to a series D round that increased the data streaming technology provider's overall funding to $70m.

Varian led a round for the targeted cancer drug developer that included existing investors such as Facit and Johnson & Johnson.

The cybersecurity software provider landed $20.6m in the Paladin Capital-led round, which featured Dell Technologies Capital and MassMutual Ventures.